<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01960725</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00049081</org_study_id>
    <secondary_id>MISP-50891</secondary_id>
    <nct_id>NCT01960725</nct_id>
  </id_info>
  <brief_title>An Alternate Dosing Schedule for Pentavalent Rotavirus Vaccine (RotaTeq)</brief_title>
  <official_title>An Open-label, Pilot Study to Compare the Safety and Immunogenicity of an Alternate Dosing Schedule (2-5 Weeks, 2 Months, and 4 Months) for Pentavalent Rotavirus Vaccine (RotaTeq) to the Standard Recommended Schedule (2, 4, and 6 Months)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dennis Clements</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study to assess the safety and immunogenicity of pentavalent rotavirus
      vaccine (RV5) when administered according to an alternate dosing schedule (2-5 weeks, 2
      months and 4 months). In this interventional, open-label study, infants 2 through 5 weeks of
      age (14 to 41 days) will be enrolled and vaccinated with RV5 according to a 2-5 week, 2 and 4
      month schedule and infants 2 months of age (56 to 83 days) will be vaccinated according to
      the standard recommended schedule (2, 4, and 6 months of age). Sera will be obtained from
      subjects one month following the final dose of vaccine and will be assayed for anti-rotavirus
      IgA and rotavirus neutralizing antibody responses against the G1, G2, G3, G4 and P[8]
      serotypes. Post dose 3 G1 serum-neutralizing antibody (SNA) geometric mean titers (GMTs) will
      be compared between children receiving pentavalent rotavirus vaccine (RV5) according to the
      alternate dosing schedule versus the standard recommended schedule. Likewise, post dose 3 G2,
      G3, G4 and P[8] SNA and serum rotavirus IgA GMTs will be compared between children receiving
      RV5 according to the alternate dosing schedule and the standard recommended schedule. The
      safety and tolerability of RV5 in children receiving vaccine according to the alternate
      dosing schedule will be described.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>G1 Serum-neutralizing Antibody</measure>
    <time_frame>1 month following vaccine series completion</time_frame>
    <description>Post dose 3 G1 serum-neutralizing antibody (SNA) geometric mean titer (GMT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>G2 Serum-neutralizing Antibody</measure>
    <time_frame>1 month following vaccine series completion</time_frame>
    <description>Post dose 3 G2 serum-neutralizing antibody(SNA) geometric mean titer (GMT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>G3 Serum-neutralizing Antibody</measure>
    <time_frame>1 month following vaccine series completion</time_frame>
    <description>Post dose 3 G3 serum-neutralizing antibody(SNA) geometric mean titer (GMT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>G4 Serum-neutralizing Antibody</measure>
    <time_frame>1 month following vaccine series completion</time_frame>
    <description>Post dose 3 G4 serum-neutralizing antibody(SNA) geometric mean titer (GMT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P1 Serum-neutralizing Antibody</measure>
    <time_frame>1 month following vaccine series completion</time_frame>
    <description>Post dose 3 P1 serum-neutralizing antibody(SNA) geometric mean titer (GMT)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum Rotavirus Immunoglobulin A</measure>
    <time_frame>1 month following vaccine series completion</time_frame>
    <description>Post dose 3 serum rotavirus Immunoglobulin A geometric mean titer (GMT)</description>
  </other_outcome>
  <other_outcome>
    <measure>Reactogenicity Assessment</measure>
    <time_frame>7 days after each dose, up to 10 months post-vaccination</time_frame>
    <description>Proportions of subjects in each vaccine group reporting a reactogenicity event in the period following each dose and any dose of RV5 will be determined</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse Event Assessment</measure>
    <time_frame>28 days after each dose, up to 10 months post-vaccination</time_frame>
    <description>Proportions of subjects in each vaccine group reporting an adverse event in the period following each dose and any dose of RV5 will be determined</description>
  </other_outcome>
  <other_outcome>
    <measure>Serious Adverse Event Assessment</measure>
    <time_frame>After each dose and up to 10 months post-vaccination</time_frame>
    <description>Proportions of subjects in each vaccine group reporting an adverse event in the period following each dose and any dose of RV5 will be determined</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Diarrhea</condition>
  <condition>Gastroenteritis</condition>
  <arm_group>
    <arm_group_label>Standard Dosing Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group will receive RV5 vaccine at 2, 4, and 6 months of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alternate Dosing Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group will receive RV5 vaccine at 2-5 weeks, 2 and 4 months of age</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RV5 (Pentavalent Rotavirus Vaccine)</intervention_name>
    <arm_group_label>Standard Dosing Group</arm_group_label>
    <arm_group_label>Alternate Dosing Group</arm_group_label>
    <other_name>RotaTeq</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female infants who are 14 through 41 or 56 through 83 days of age at Visit 1
             (Day of initial vaccination)

          2. Parent / legal guardian has read and signed the informed consent document

          3. Child and parent / legal guardian is available for the entire study period and can be
             reached by telephone

          4. Healthy infant as determined by medical history and by a baseline physical examination

          5. Infant weight at time of enrollment must exceed birth weight

        Exclusion Criteria:

          1. History of hypersensitivity to the vaccine or any component of the vaccine

          2. History of Severe Combined Immunodeficiency Disease (SCID)

          3. History of immunocompromise ( infant is known to be HIV positive, to have
             hypogammaglobulinemia or to have an underlying malignancy)

          4. History of intussusception

          5. Any clinically significant history of gastrointestinal disease including active acute
             gastrointestinal illness, chronic diarrhea, failure to thrive, congenital abdominal
             disorders, abdominal surgery or liver disease

          6. Prior receipt of a rotavirus vaccine

          7. Less than 37 weeks gestation

          8. The subject has participated in a study with an experimental agent within one month of
             enrollment in the study or anticipated receipt of an experimental agent during
             participation in the study

          9. Receipt of blood products within 4 weeks of study vaccination

         10. Receipt of a live virus vaccine within 4 weeks of study vaccination or an inactivated
             vaccine within 2 weeks. Concomitant administration of routinely recommended vaccines
             is allowed. A dose of hepatitis B vaccine administered in the birthing hospital is
             permitted. Planned routine use of inactivated influenza vaccine for children over 6
             months of age is permitted.

         11. Acute illness within 48 hours of vaccination (axillary temperature of 100.4Â°F or
             higher, 3 or more grossly watery stools, vomiting). (Infants with stable unchanged
             gastroesophageal reflux may be enrolled).

         12. Insufficient weight gain requiring future weight checks in addition to routine
             scheduled well child visits

         13. The subject has any condition that the investigator believes would put the subject at
             an increased risk of injury or would render the subject unable to complete the trial
             or fulfill the requirements of the study protocol.

         14. Household contact who is immunodeficient (any malignancies or otherwise
             immunocompromised, primary immunodeficiency, receiving immunosuppressive therapy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>83 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis A Clements, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Health System</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2013</study_first_submitted>
  <study_first_submitted_qc>October 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2013</study_first_posted>
  <results_first_submitted>November 8, 2016</results_first_submitted>
  <results_first_submitted_qc>March 10, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 21, 2017</results_first_posted>
  <last_update_submitted>March 10, 2017</last_update_submitted>
  <last_update_submitted_qc>March 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Dennis Clements</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Gastroenteritis</keyword>
  <keyword>Diarrhea</keyword>
  <keyword>Rotavirus</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Dehydration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
    <mesh_term>Gastroenteritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group A: Standard Dosing</title>
          <description>Group will receive RV5 vaccine at 2, 4, and 6 months of age
RV5 (Pentavalent Rotavirus Vaccine)</description>
        </group>
        <group group_id="P2">
          <title>Group B: Alternate Dosing</title>
          <description>Group will receive RV5 vaccine at 2-5 weeks, 2 and 4 months of age
RV5 (Pentavalent Rotavirus Vaccine)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received First Vaccine</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Recieved Second Vaccine</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Third Vaccine</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>unable to obtain blood sample</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group A: Standard Dosing</title>
          <description>Group will receive RV5 vaccine at 2, 4, and 6 months of age
RV5 (Pentavalent Rotavirus Vaccine)</description>
        </group>
        <group group_id="B2">
          <title>Group B: Alternate Dosing</title>
          <description>Group will receive RV5 vaccine at 2-5 weeks, 2 and 4 months of age
RV5 (Pentavalent Rotavirus Vaccine)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="66"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" spread="4.6"/>
                    <measurement group_id="B2" value="26.6" spread="7.3"/>
                    <measurement group_id="B3" value="44.8" spread="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>G1 Serum-neutralizing Antibody</title>
        <description>Post dose 3 G1 serum-neutralizing antibody (SNA) geometric mean titer (GMT)</description>
        <time_frame>1 month following vaccine series completion</time_frame>
        <population>The per protocol analysis population includes participants who met all inclusion and exclusion criteria, received all scheduled study vaccinations, and who contributed post-vaccination blood samples for testing for which valid results were reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Standard Dosing</title>
            <description>Group will receive RV5 vaccine at 2, 4, and 6 months of age
RV5 (Pentavalent Rotavirus Vaccine)</description>
          </group>
          <group group_id="O2">
            <title>Group B: Alternate Dosing</title>
            <description>Group will receive RV5 vaccine at 2-5 weeks, 2 and 4 months of age
RV5 (Pentavalent Rotavirus Vaccine)</description>
          </group>
        </group_list>
        <measure>
          <title>G1 Serum-neutralizing Antibody</title>
          <description>Post dose 3 G1 serum-neutralizing antibody (SNA) geometric mean titer (GMT)</description>
          <population>The per protocol analysis population includes participants who met all inclusion and exclusion criteria, received all scheduled study vaccinations, and who contributed post-vaccination blood samples for testing for which valid results were reported.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188" lower_limit="117.9" upper_limit="299.7"/>
                    <measurement group_id="O2" value="184.5" lower_limit="117" upper_limit="290.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>G2 Serum-neutralizing Antibody</title>
        <description>Post dose 3 G2 serum-neutralizing antibody(SNA) geometric mean titer (GMT)</description>
        <time_frame>1 month following vaccine series completion</time_frame>
        <population>The per protocol analysis population includes participants who met all inclusion and exclusion criteria, received all scheduled study vaccinations, and who contributed post-vaccination blood samples for testing for which valid results were reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Standard Dosing</title>
            <description>Group will receive RV5 vaccine at 2, 4, and 6 months of age
RV5 (Pentavalent Rotavirus Vaccine)</description>
          </group>
          <group group_id="O2">
            <title>Group B: Alternate Dosing</title>
            <description>Group will receive RV5 vaccine at 2-5 weeks, 2 and 4 months of age
RV5 (Pentavalent Rotavirus Vaccine)</description>
          </group>
        </group_list>
        <measure>
          <title>G2 Serum-neutralizing Antibody</title>
          <description>Post dose 3 G2 serum-neutralizing antibody(SNA) geometric mean titer (GMT)</description>
          <population>The per protocol analysis population includes participants who met all inclusion and exclusion criteria, received all scheduled study vaccinations, and who contributed post-vaccination blood samples for testing for which valid results were reported.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.7" lower_limit="25" upper_limit="59.9"/>
                    <measurement group_id="O2" value="33.1" lower_limit="20.7" upper_limit="52.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>G3 Serum-neutralizing Antibody</title>
        <description>Post dose 3 G3 serum-neutralizing antibody(SNA) geometric mean titer (GMT)</description>
        <time_frame>1 month following vaccine series completion</time_frame>
        <population>The per protocol analysis population includes participants who met all inclusion and exclusion criteria, received all scheduled study vaccinations, and who contributed post-vaccination blood samples for testing for which valid results were reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Standard Dosing</title>
            <description>Group will receive RV5 vaccine at 2, 4, and 6 months of age
RV5 (Pentavalent Rotavirus Vaccine)</description>
          </group>
          <group group_id="O2">
            <title>Group B: Alternate Dosing</title>
            <description>Group will receive RV5 vaccine at 2-5 weeks, 2 and 4 months of age
RV5 (Pentavalent Rotavirus Vaccine)</description>
          </group>
        </group_list>
        <measure>
          <title>G3 Serum-neutralizing Antibody</title>
          <description>Post dose 3 G3 serum-neutralizing antibody(SNA) geometric mean titer (GMT)</description>
          <population>The per protocol analysis population includes participants who met all inclusion and exclusion criteria, received all scheduled study vaccinations, and who contributed post-vaccination blood samples for testing for which valid results were reported.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.1" lower_limit="27.5" upper_limit="64.6"/>
                    <measurement group_id="O2" value="27.3" lower_limit="17.3" upper_limit="43.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>G4 Serum-neutralizing Antibody</title>
        <description>Post dose 3 G4 serum-neutralizing antibody(SNA) geometric mean titer (GMT)</description>
        <time_frame>1 month following vaccine series completion</time_frame>
        <population>The per protocol analysis population includes participants who met all inclusion and exclusion criteria, received all scheduled study vaccinations, and who contributed post-vaccination blood samples for testing for which valid results were reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Standard Dosing</title>
            <description>Group will receive RV5 vaccine at 2, 4, and 6 months of age
RV5 (Pentavalent Rotavirus Vaccine)</description>
          </group>
          <group group_id="O2">
            <title>Group B: Alternate Dosing</title>
            <description>Group will receive RV5 vaccine at 2-5 weeks, 2 and 4 months of age
RV5 (Pentavalent Rotavirus Vaccine)</description>
          </group>
        </group_list>
        <measure>
          <title>G4 Serum-neutralizing Antibody</title>
          <description>Post dose 3 G4 serum-neutralizing antibody(SNA) geometric mean titer (GMT)</description>
          <population>The per protocol analysis population includes participants who met all inclusion and exclusion criteria, received all scheduled study vaccinations, and who contributed post-vaccination blood samples for testing for which valid results were reported.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144.6" lower_limit="105.1" upper_limit="198.8"/>
                    <measurement group_id="O2" value="66.5" lower_limit="50.7" upper_limit="87.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>P1 Serum-neutralizing Antibody</title>
        <description>Post dose 3 P1 serum-neutralizing antibody(SNA) geometric mean titer (GMT)</description>
        <time_frame>1 month following vaccine series completion</time_frame>
        <population>The per protocol analysis population includes participants who met all inclusion and exclusion criteria, received all scheduled study vaccinations, and who contributed post-vaccination blood samples for testing for which valid results were reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Standard Dosing</title>
            <description>Group will receive RV5 vaccine at 2, 4, and 6 months of age
RV5 (Pentavalent Rotavirus Vaccine)</description>
          </group>
          <group group_id="O2">
            <title>Group B: Alternate Dosing</title>
            <description>Group will receive RV5 vaccine at 2-5 weeks, 2 and 4 months of age
RV5 (Pentavalent Rotavirus Vaccine)</description>
          </group>
        </group_list>
        <measure>
          <title>P1 Serum-neutralizing Antibody</title>
          <description>Post dose 3 P1 serum-neutralizing antibody(SNA) geometric mean titer (GMT)</description>
          <population>The per protocol analysis population includes participants who met all inclusion and exclusion criteria, received all scheduled study vaccinations, and who contributed post-vaccination blood samples for testing for which valid results were reported.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.7" lower_limit="77.51" upper_limit="169.6"/>
                    <measurement group_id="O2" value="136.5" lower_limit="84.91" upper_limit="219.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum Rotavirus Immunoglobulin A</title>
        <description>Post dose 3 serum rotavirus Immunoglobulin A geometric mean titer (GMT)</description>
        <time_frame>1 month following vaccine series completion</time_frame>
        <population>The per protocol analysis population includes participants who met all inclusion and exclusion criteria, received all scheduled study vaccinations, and who contributed post-vaccination blood samples for testing for which valid results were reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Standard Dosing</title>
            <description>Group will receive RV5 vaccine at 2, 4, and 6 months of age
RV5 (Pentavalent Rotavirus Vaccine)</description>
          </group>
          <group group_id="O2">
            <title>Group B: Alternate Dosing</title>
            <description>Group will receive RV5 vaccine at 2-5 weeks, 2 and 4 months of age
RV5 (Pentavalent Rotavirus Vaccine)</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Rotavirus Immunoglobulin A</title>
          <description>Post dose 3 serum rotavirus Immunoglobulin A geometric mean titer (GMT)</description>
          <population>The per protocol analysis population includes participants who met all inclusion and exclusion criteria, received all scheduled study vaccinations, and who contributed post-vaccination blood samples for testing for which valid results were reported.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="318.3" lower_limit="179.7" upper_limit="563.8"/>
                    <measurement group_id="O2" value="183.7" lower_limit="93.37" upper_limit="361.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Reactogenicity Assessment</title>
        <description>Proportions of subjects in each vaccine group reporting a reactogenicity event in the period following each dose and any dose of RV5 will be determined</description>
        <time_frame>7 days after each dose, up to 10 months post-vaccination</time_frame>
        <population>Proportions of subjects in each vaccine group reporting a reactogenicity event in the period following each dose and any does of RV5 will be determined</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Standard Dosing</title>
            <description>Group will receive RV5 vaccine at 2, 4, and 6 months of age
RV5 (Pentavalent Rotavirus Vaccine)</description>
          </group>
          <group group_id="O2">
            <title>Group B: Alternate Dosing</title>
            <description>Group will receive RV5 vaccine at 2-5 weeks, 2 and 4 months of age
RV5 (Pentavalent Rotavirus Vaccine)</description>
          </group>
        </group_list>
        <measure>
          <title>Reactogenicity Assessment</title>
          <description>Proportions of subjects in each vaccine group reporting a reactogenicity event in the period following each dose and any dose of RV5 will be determined</description>
          <population>Proportions of subjects in each vaccine group reporting a reactogenicity event in the period following each dose and any does of RV5 will be determined</population>
          <units>Proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06"/>
                    <measurement group_id="O2" value="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15"/>
                    <measurement group_id="O2" value="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21"/>
                    <measurement group_id="O2" value="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adverse Event Assessment</title>
        <description>Proportions of subjects in each vaccine group reporting an adverse event in the period following each dose and any dose of RV5 will be determined</description>
        <time_frame>28 days after each dose, up to 10 months post-vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A: Standard Dosing</title>
            <description>Group will receive RV5 vaccine at 2, 4, and 6 months of age
RV5 (Pentavalent Rotavirus Vaccine)</description>
          </group>
          <group group_id="O2">
            <title>Group B: Alternate Dosing</title>
            <description>Group will receive RV5 vaccine at 2-5 weeks, 2 and 4 months of age
RV5 (Pentavalent Rotavirus Vaccine)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Event Assessment</title>
          <description>Proportions of subjects in each vaccine group reporting an adverse event in the period following each dose and any dose of RV5 will be determined</description>
          <units>Proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27"/>
                    <measurement group_id="O2" value="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06"/>
                    <measurement group_id="O2" value="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post dose 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03"/>
                    <measurement group_id="O2" value="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post any dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30"/>
                    <measurement group_id="O2" value="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serious Adverse Event Assessment</title>
        <description>Proportions of subjects in each vaccine group reporting an adverse event in the period following each dose and any dose of RV5 will be determined</description>
        <time_frame>After each dose and up to 10 months post-vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A: Standard Dosing</title>
            <description>Group will receive RV5 vaccine at 2, 4, and 6 months of age
RV5 (Pentavalent Rotavirus Vaccine)</description>
          </group>
          <group group_id="O2">
            <title>Group B: Alternate Dosing</title>
            <description>Group will receive RV5 vaccine at 2-5 weeks, 2 and 4 months of age
RV5 (Pentavalent Rotavirus Vaccine)</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Event Assessment</title>
          <description>Proportions of subjects in each vaccine group reporting an adverse event in the period following each dose and any dose of RV5 will be determined</description>
          <units>Proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious Adverse Event-Post dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Adverse Event-Post dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Adverse Event-Post dose 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 days after each dose, up to 10 months post-vaccination</time_frame>
      <desc>Proportions of subjects in each vaccine group reporting a reactogenicity event in the period following each dose and any dose of RV5 will be determined.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group A: Standard Dosing</title>
          <description>Group will receive RV5 vaccine at 2, 4, and 6 months of age
RV5 (Pentavalent Rotavirus Vaccine)</description>
        </group>
        <group group_id="E2">
          <title>Group B: Alternate Dosing</title>
          <description>Group will receive RV5 vaccine at 2-5 weeks, 2 and 4 months of age
RV5 (Pentavalent Rotavirus Vaccine)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Ear Drainage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="33"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Change in stool</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Gastrointestanal upset</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Poor weight gain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Excessive sleepiness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Sleeplessness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Change in appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Motor vehicale accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>URI</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diaper rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Macule on chin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Dennis Clements</name_or_title>
      <organization>Duke University School of Medicine</organization>
      <phone>919-684-7790</phone>
      <email>dennis.clements@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

